search
Back to results

Study of SGN1 in Patients With Advanced Solid Tumor

Primary Purpose

Advanced Solid Tumor

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
SGN1
Sponsored by
Guangzhou Sinogen Pharmaceutical Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Advanced Solid Tumor

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Participants must meet all the following inclusion criteria:

    1. Age 18-75 years inclusive of end value, regardless of gender.
    2. Part 1: Patients with advanced stage (unresectable or metastatic) cancer including but not limited to small cell lung cancer, non-small cell lung cancer (adeno- and squamous), Hodgkin's lymphoma or non-Hodgkin's lymphoma, sarcoma, cervical carcinoma, melanoma, head and neck cancer, breast cancer, ovarian cancer, pseudomyxoma peritoneum (Pseudomyxoma peritonei, PMP) and hepatocellular carcinoma characterized by failure of standard treatment (disease progression or intolerance, such as chemotherapy, targeted therapy, and other immunotherapies) or patients who have no standard treatment or patients who are unable to receive standard treatment.

      Part 3: Patients who meet all the standards above and should be the selected tumor type according to part1&2.

    3. Patients finished anti-tumor therapy including chemotherapy, immunotherapy, biological agents, hormone therapy, radiotherapy (except local radiotherapy for pain relief) ≥ 4 weeks prior to the first dose of study drug.
    4. At least 1 measurable lesion according to RECIST 1.1 (for solid tumors).
    5. Patients have recovered from any toxic reaction to previous medications (≤Grade 1 based on NCI-CTCAE v 5.0, except a. Hair loss; b. Pigmentation; c. The long-term toxicity caused by radiotherapy and cannot be recovered by the investigator's judgment; d. Platinum induced neurotoxicity of grade 2 and below; e. Hemoglobin at 90 ~ 100 g / L (including boundary value)) or stable status assessed by the investigator.
    6. Eastern Co-Operative Oncology Group (ECOG) performance status 0 ~ 1 and a life expectancy of at least 3 months.
    7. Laboratory tests must meet the following requirements and have not received any blood cell growth factor 14 days before the test (Patients with laboratory values outside of the specified ranges will be permitted to be retested once in order to meet the criteria), rescreening for Hemoglobin, ALT, AST and coagulation function is allowed but only allowed once:

      1. absolute count of neutrophils (ANC) ≥1.5×109 /L, platelet ≥75×109 /L; Hemoglobin ≥90 g/L ;
      2. serum albumin ≥ 25g /L; Bilirubin ≤1.5 × ULN, ALT and AST ≤2.5 × ULN;
      3. In patients with liver metastasis, ALT and AST≤5 × ULN ;
      4. Creatinine clearance ≥50 mL/min (standard Cockcroft -Gault formula) or Cr ≤1.5 ×ULN: urinary protein ≥2+ or urinary protein quantitative <1.0 g/L
      5. International standardized ratio of coagulation function (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
    8. If female, be either postmenopausal for at least 1 year with documented follicle stimulating hormone (FSH) >30 IU/L, or surgically sterile for at least 3 months, or if a woman of childbearing potential, must be non-pregnant confirmed by blood and urine pregnancy tests, and non-lactating.
    9. Female patients of childbearing potential must agree to use acceptable method(s) of contraception from consent through at least 6 months after drug infusion.
    10. Male patients of reproductive capacity must agree to use effective contraception from start of mobilization through at least 6 months after drug infusion
    11. Patients with chronic HBV infection with active disease who meet the criteria for anti HBV therapy (HBV DNA test is less than 2000 IU/ml) should be on a suppressive antiviral therapy prior to initiation of cancer therapy. Patients with a history of HCV infection should have completed curative antiviral treatment and HCV viral load below the limit of quantification. Patients with HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Patients on concurrent HCV treatment should have HCV below the limit of quantification.
    12. Patients must be able to follow up after the treatment.
    13. Patients must understand and voluntarily sign the informed consent form.

Exclusion Criteria:

  • Patients will be excluded from participation for any of the following criteria:

    1. Received systemic or absorbable dosage of steroid hormone (prednisone or equivalent) of >10 mg/day in the 14 days prior to enrollment;

      1. Prednisone >10 mg/day
      2. Dexamethasone >1.5 mg/day.
    2. Currently using antibiotic.
    3. Tumors in hollow organs (Stomach, esophagus, intestine, urinary tract etc.).
    4. Present with symptomatic central nervous system metastasis or brain abscess at screening.
    5. Present with diverticulitis or conditions at screening that might promote the unintentional growth of anaerobic bacteria in nontarget lesions.
    6. Existing cardiac clinical symptoms or diseases that cannot be well controlled, such as:

      1. NYHA grade 2 or above heart failure;
      2. Unstable angina pectoris;
      3. Myocardial infarction occurred within 1 year;
      4. Patients with supraventricular or ventricular arrhythmias that have clinical significance and need treatment or intervention;
      5. Uncontrolled hypertension (systolic blood pressure) ≥160 mmHg and (diastolic blood pressure) ≥100 mmHg after drug treatment;
      6. Patients with valvular heart disease or mitral valve prolapse, aortic valve disease or other source of turbulent cardiac blood flow.
    7. Those who had received radiotherapy, chemotherapy, hormone therapy, surgery or molecular targeted therapy that ended fewer than 4 weeks before the first dose of study treatment (if nitrosourea or mitomycin chemotherapy,the interval between end of chemotherapy and first dose of study treatment must be no less than 6 weeks).
    8. Patients with active or uncontrolled infection or fever, >38.5℃, of unknown cause during screening or before the first administration of the study drug (according to the judgment of the researcher, fever caused by tumor can be included).
    9. Positive for the presence of human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) (positive antigen/antibody and nucleic acid tests); or follow standard of care for HIV diagnosis.
    10. Patients with Anti-TP positive.
    11. Patients participating in other clinical studies or participating in other clinical studies within 4 weeks (or 5 half-lives of other study drugs) prior to enrollment and receiving experimental drug administration.
    12. Vaccination within 28 days of the first trial treatment, except for administration of inactivated vaccines and RNA vaccines (e.g., inactivated influenza vaccines and COVID-19 RNA vaccines) ;
    13. Received live or attenuated vaccines within 4 weeks of study drug administration, during treatment, or within 5 months of the last administration.
    14. In the judgment of the investigator, there are other factors that may lead to termination: for example, other serious diseases (including mental diseases) need to be treated together, there are serious abnormalities in laboratory examination, family or social factors, which may affect the safety of the patients or test data and sample collection.
    15. In the researcher's judgment, patients who are not suitable for other reasons.
    16. Documented salmonella infections within 6 months.
    17. Allergic to any study medications or rescue medications.
    18. Patients with implants such as pacemakers, prosthetic cardiac valves, or metal orthopedic prostheses.

Sites / Locations

  • Banner MD Anderson Cancer CenterRecruiting
  • Health Chao Family Comprehensive Cancer CenterRecruiting
  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer CenterRecruiting
  • University of Cincinnati Cancer CenterRecruiting
  • China Medical University HospitalRecruiting
  • Taipei Medical University HospitalRecruiting
  • Taipei Veterans General HospitalRecruiting
  • Linkou Chang Gung Memorial HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cohort

Arm Description

Cohorts of 3 patients will be enrolled. The first patient of each cohort in Part 1 will be admitted to an infusion unit and treated with an IV infusion of SGN1 over 2 hours. All dosed patients will be closely evaluated for DLTs for 28 days post first dose. Up to 5 cohorts will be evaluated. Part 3 is an open-label study designed to adopt the optimal biologic dose in no more than 2 specific tumor subtypes. The tumor types will be selected based on safety and preliminary efficacy evaluated in Part 1&2.

Outcomes

Primary Outcome Measures

Incidence and severity of AEs (adverse events).
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. Events meeting the definition of an AE include: Any abnormal laboratory test results (hematology, serum chemistry, or urinalysis) or other safety assessments (e.g., ECGs, vital signs measurements), including those that worsen from baseline, and was felt to be clinically significant in the medical and scientific judgment of the Investigator. Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. New conditions detected or diagnosed after study treatment administration even though it may have been present prior to the start of the study. Signs, symptoms, or the clinical sequelae of a suspected interaction.
Incidence of SAEs.
An AE or suspected adverse reaction is considered "serious" if it results in any of the following outcomes: Death Life-threatening Inpatient hospitalization or prolongation of existing hospitalization A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions A congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.
Objective response rate (ORR)
The efficacy endpoints include ORR, DCR and PFS. The ORR is defined as the proportion of patients who achieve PR or better according to the RECIST v1.1, mRECIST is used to assess Hepatocellular carcinoma, and LYRIC is used to assess Lymphoma. as assessed by investigator.
Disease control rate (DCR)
The efficacy endpoints include ORR, DCR and PFS. The DCR is defined as the proportion of patients who achieve SD or better according to the RECIST v1.1, mRECIST is used to assess Hepatocellular carcinoma, and LYRIC is used to assess Lymphoma. as assessed by investigator.
Progress Free Survival (PFS)
The efficacy endpoints include ORR, DCR and PFS. PFS is defined as the time interval from date of first dose of SGN1 to the date of documented disease progression (iRECIST is used when the subject is suspected to have pseudo disease progression) or death due to any cause, whichever occurs first.

Secondary Outcome Measures

Incidence with any dose limiting toxicity (DLT),to determine the MTD.
Any of the following judged to be associated with SGN1 (i.e., possibly-, probably-, or definitely related to), may be considered a DLT: Any Grade 5 adverse event that is at least possibly related to investigational drug Grade 4 non-hematological toxicities (excluding alopecia) of any duration Grade 3 non-hematologic (non-laboratory) toxicity lasting at least 7 days despite optimal supportive care Any Grade 3 non-hematologic laboratory value if: a) medical intervention is required to treat the patient; or b) the abnormality leads to hospitalization; or c) the abnormality persists for at least 7 days Grade 4 hematologic toxicity, other than those specified in criteria 6 and 7 below, lasting longer than 7 days Grade 3 or Grade 4 febrile neutropenia of any duration Grade 3 thrombocytopenia in combination with a Grade 3 or greater blood and lymphatic system disorder Grade 3 AST or ALT that is associated with a Grade 2 or greater rise in bilirubin.
Incidence with adverse events and preliminary efficacy data to determine the OBD.
OBD will be determined by adverse events, preliminary efficacy data,and the OBD determined by the SMC.
PK analysis of SGN1 level in blood.
Concentrations of SGN1 will be measured. In Part 1, blood sampling for pharmacokinetics will be conducted for pharmacokinetics (PK) during the first dose.
Bacterial shedding of SGN1 level in blood.
Blood samples for both PK and bacterial shedding will be collected and processed in the same manner for the first SGN1 administration. For subsequent SGN1 infusions (starting with Dose 2), blood samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If blood samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, blood samples for bacterial shedding will be collected.
Bacterial shedding of SGN1 level in urine.
For the first SGN1 administration (C1D1), urine sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), urine samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If urine samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, urine samples for bacterial shedding will be collected.
Bacterial shedding of SGN1 level in saliva.
For the first SGN1 administration (C1D1), saliva sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), saliva samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If saliva samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, saliva samples for bacterial shedding will be collected.
Bacterial shedding of SGN1 level in feces.
For the first SGN1 administration (C1D1), feces sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), will be collected by the subject within 24 hours prior to infusion and within 24 hours after the end of infusion. If feces samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, feces samples will be collected by the patient within 24 hours prior to the EOT/ET visit.
Assessment of tumor colonization.
For appropriate superficial tumors, colonization of the tumor by SGN1 will be assessed by fine needle aspiration and/or excise biopsies every 8 weeks.
Proinflammatory cytokines
Proinflammatory cytokines including IL-1β, IFN-γ,TNF-α, IL-6, and IL-8.

Full Information

First Posted
August 24, 2021
Last Updated
September 28, 2023
Sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Collaborators
ClinChoice Enterprise Management (Shanghai) Limited, Parexel
search

1. Study Identification

Unique Protocol Identification Number
NCT05038150
Brief Title
Study of SGN1 in Patients With Advanced Solid Tumor
Official Title
Phase I/IIa, Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Modified Salmonella Typhimurium SGN1 in Patients With Advanced Solid Tumor
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 16, 2023 (Actual)
Primary Completion Date
February 28, 2024 (Anticipated)
Study Completion Date
August 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Collaborators
ClinChoice Enterprise Management (Shanghai) Limited, Parexel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1, a genetically modified strain of Salmonella enterica, serotype typhimurium that expresses L-Methioninase,in participants with refractory solid tumors. Study Rationale:The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. Patient Population:The treatment populations shall be patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.
Detailed Description
Methionine starvation can powerfully modulate DNA methylation, cell cycle transition, polyamines and antioxidant synthesis of tumor cells, in contrast to normal ones. L-Methioninase is a pyridoxal phosphate dependent enzyme that catalyzes the γ-elimination reaction of L-methionine to methanethiol, α-ketobutyrate and ammonia. Absolute-dependency on exogenous supply of L-methionine, not homocysteine, for growth and proliferation of tumors is the pivotal biochemical criterion for various human cancers. SGN1 is a genetically modified strain of Salmonella enterica, serotype typhimurium that expresses L-Methioninase. The attenuated live bacterium has been investigated in China for utility in treating advanced solid tumors. The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. This study is a multi-center phase I/IIa clinical trial with 3 parts: Part 1 & 2 is an open-label, dose escalation phase. Part 1 is the DLT observation period, and the patients will enter part 2 for extension treatment after completing the 28-day DLT observation period. In part 1& 2 of the study will employ a standard 3 + 3 escalating dose design to explore dose limiting toxicities (DLTs) in sequential cohorts to select the maximum tolerated dose (MTD). In part 2, the treatment may be terminated if the patients withdraws, has unacceptable toxicity, develops disease progression, experiences an AE that cannot be resolved with/without rescue medication and cause stopping study drug for 2 planned administrations, death, or loss to follow-up. In such cases, patients will be discontinued and palliative or rescue therapy will be offered to those that terminate early.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Advanced Solid Tumor

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
The study will employ a standard 3 + 3 escalating dose design to explore dose limiting toxicities (DLTs). Currently plans to evaluate 5 cohorts with 3- 6 patients to determine the Maximum Tolerated Dose (MTD). Patients who had no dose-limiting toxicities observed in Part 1 proceeded to Part 2. Alternatively, if a DLT occurs in only 1/3 patients at any dose, then the SMC will review the data and determine if 3 more patients should be enrolled at this dose level. If this is the highest dose and there have been no DLTs-then 3 more patients must be evaluated at the same dose level to confirm the MTD. The MTD is defined as the highest dose at which no more than one (1) DLT is observed among 6 patients. Part 3 is an open-label study designed to adopt the optimal biologic dose in no more than 2 specific tumor subtypes. The tumor types will be selected based on safety and preliminary efficacy evaluated in Part 1&2.
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort
Arm Type
Experimental
Arm Description
Cohorts of 3 patients will be enrolled. The first patient of each cohort in Part 1 will be admitted to an infusion unit and treated with an IV infusion of SGN1 over 2 hours. All dosed patients will be closely evaluated for DLTs for 28 days post first dose. Up to 5 cohorts will be evaluated. Part 3 is an open-label study designed to adopt the optimal biologic dose in no more than 2 specific tumor subtypes. The tumor types will be selected based on safety and preliminary efficacy evaluated in Part 1&2.
Intervention Type
Drug
Intervention Name(s)
SGN1
Other Intervention Name(s)
SalMet-Vec
Intervention Description
SGN1, will be administered as an IV infusion, via an IV catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.
Primary Outcome Measure Information:
Title
Incidence and severity of AEs (adverse events).
Description
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. Events meeting the definition of an AE include: Any abnormal laboratory test results (hematology, serum chemistry, or urinalysis) or other safety assessments (e.g., ECGs, vital signs measurements), including those that worsen from baseline, and was felt to be clinically significant in the medical and scientific judgment of the Investigator. Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. New conditions detected or diagnosed after study treatment administration even though it may have been present prior to the start of the study. Signs, symptoms, or the clinical sequelae of a suspected interaction.
Time Frame
From receiving study drug and throughout the study, until 28 days after the last dosing.
Title
Incidence of SAEs.
Description
An AE or suspected adverse reaction is considered "serious" if it results in any of the following outcomes: Death Life-threatening Inpatient hospitalization or prolongation of existing hospitalization A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions A congenital anomaly/birth defect Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.
Time Frame
From receiving study drug and throughout the study, until 28 days after the last dosing.
Title
Objective response rate (ORR)
Description
The efficacy endpoints include ORR, DCR and PFS. The ORR is defined as the proportion of patients who achieve PR or better according to the RECIST v1.1, mRECIST is used to assess Hepatocellular carcinoma, and LYRIC is used to assess Lymphoma. as assessed by investigator.
Time Frame
From signing the informed consent form until 28 days after the last dose.
Title
Disease control rate (DCR)
Description
The efficacy endpoints include ORR, DCR and PFS. The DCR is defined as the proportion of patients who achieve SD or better according to the RECIST v1.1, mRECIST is used to assess Hepatocellular carcinoma, and LYRIC is used to assess Lymphoma. as assessed by investigator.
Time Frame
From signing the informed consent form until 28 days after the last dose.
Title
Progress Free Survival (PFS)
Description
The efficacy endpoints include ORR, DCR and PFS. PFS is defined as the time interval from date of first dose of SGN1 to the date of documented disease progression (iRECIST is used when the subject is suspected to have pseudo disease progression) or death due to any cause, whichever occurs first.
Time Frame
From signing the informed consent form until 28 days after the last dose.
Secondary Outcome Measure Information:
Title
Incidence with any dose limiting toxicity (DLT),to determine the MTD.
Description
Any of the following judged to be associated with SGN1 (i.e., possibly-, probably-, or definitely related to), may be considered a DLT: Any Grade 5 adverse event that is at least possibly related to investigational drug Grade 4 non-hematological toxicities (excluding alopecia) of any duration Grade 3 non-hematologic (non-laboratory) toxicity lasting at least 7 days despite optimal supportive care Any Grade 3 non-hematologic laboratory value if: a) medical intervention is required to treat the patient; or b) the abnormality leads to hospitalization; or c) the abnormality persists for at least 7 days Grade 4 hematologic toxicity, other than those specified in criteria 6 and 7 below, lasting longer than 7 days Grade 3 or Grade 4 febrile neutropenia of any duration Grade 3 thrombocytopenia in combination with a Grade 3 or greater blood and lymphatic system disorder Grade 3 AST or ALT that is associated with a Grade 2 or greater rise in bilirubin.
Time Frame
Up to 28 days post first dose.
Title
Incidence with adverse events and preliminary efficacy data to determine the OBD.
Description
OBD will be determined by adverse events, preliminary efficacy data,and the OBD determined by the SMC.
Time Frame
From receiving study drug and throughout the study, until 28 days after the last dosing.
Title
PK analysis of SGN1 level in blood.
Description
Concentrations of SGN1 will be measured. In Part 1, blood sampling for pharmacokinetics will be conducted for pharmacokinetics (PK) during the first dose.
Time Frame
Pre-dose,30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 2 hours 20 minutes, 2 hours 40 minutes, 3 hours, 3 hours 30 minutes, 4 hours, 5 hours, 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours after the start first dose.
Title
Bacterial shedding of SGN1 level in blood.
Description
Blood samples for both PK and bacterial shedding will be collected and processed in the same manner for the first SGN1 administration. For subsequent SGN1 infusions (starting with Dose 2), blood samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If blood samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, blood samples for bacterial shedding will be collected.
Time Frame
Before the first administration up to 28 days after the last dosing.
Title
Bacterial shedding of SGN1 level in urine.
Description
For the first SGN1 administration (C1D1), urine sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), urine samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If urine samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, urine samples for bacterial shedding will be collected.
Time Frame
Before the first administration up to 28 days after the last dosing.
Title
Bacterial shedding of SGN1 level in saliva.
Description
For the first SGN1 administration (C1D1), saliva sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), saliva samples shall be collected within 2 hours prior to the start of SGN1 infusion and within 24 hours of end of infusion. If saliva samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, saliva samples for bacterial shedding will be collected.
Time Frame
Before the first administration up to 28 days after the last dosing.
Title
Bacterial shedding of SGN1 level in feces.
Description
For the first SGN1 administration (C1D1), feces sampling for bacterial shedding will be conducted. For subsequent SGN1 infusions (starting with Dose 2), will be collected by the subject within 24 hours prior to infusion and within 24 hours after the end of infusion. If feces samples test positive for SGN1, collection of shedding samples should continue with weekly SGN1 administration until the samples from three consecutive infusions result below the limit of detection (LOD). In EOT/ET visit, feces samples will be collected by the patient within 24 hours prior to the EOT/ET visit.
Time Frame
Before the first administration up to 28 days after the last dosing.
Title
Assessment of tumor colonization.
Description
For appropriate superficial tumors, colonization of the tumor by SGN1 will be assessed by fine needle aspiration and/or excise biopsies every 8 weeks.
Time Frame
From receiving study drug and throughout the study, until 28 days after the last dosing.
Title
Proinflammatory cytokines
Description
Proinflammatory cytokines including IL-1β, IFN-γ,TNF-α, IL-6, and IL-8.
Time Frame
Within 7 days prior to the first dose, and at 2, 4, 6, and 24 hours post end of first infusion.
Other Pre-specified Outcome Measures:
Title
Tumor biomarkers upon cancer types
Description
The changes before and after treatment of tumor biomarkers upon cancer types.
Time Frame
From baseline until 28 days after the last dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must meet all the following inclusion criteria: Age 18-75 years inclusive of end value, regardless of gender. Part 1: Patients with advanced stage (unresectable or metastatic) cancer including but not limited to small cell lung cancer, non-small cell lung cancer (adeno- and squamous), Hodgkin's lymphoma or non-Hodgkin's lymphoma, sarcoma, cervical carcinoma, melanoma, head and neck cancer, breast cancer, ovarian cancer, pseudomyxoma peritoneum (Pseudomyxoma peritonei, PMP) and hepatocellular carcinoma characterized by failure of standard treatment (disease progression or intolerance, such as chemotherapy, targeted therapy, and other immunotherapies) or patients who have no standard treatment or patients who are unable to receive standard treatment. Part 3: Patients who meet all the standards above and should be the selected tumor type according to part1&2. Patients finished anti-tumor therapy including chemotherapy, immunotherapy, biological agents, hormone therapy, radiotherapy (except local radiotherapy for pain relief) ≥ 4 weeks prior to the first dose of study drug. At least 1 measurable lesion according to RECIST 1.1 (for solid tumors). Patients have recovered from any toxic reaction to previous medications (≤Grade 1 based on NCI-CTCAE v 5.0, except a. Hair loss; b. Pigmentation; c. The long-term toxicity caused by radiotherapy and cannot be recovered by the investigator's judgment; d. Platinum induced neurotoxicity of grade 2 and below; e. Hemoglobin at 90 ~ 100 g / L (including boundary value)) or stable status assessed by the investigator. Eastern Co-Operative Oncology Group (ECOG) performance status 0 ~ 1 and a life expectancy of at least 3 months. Laboratory tests must meet the following requirements and have not received any blood cell growth factor 14 days before the test (Patients with laboratory values outside of the specified ranges will be permitted to be retested once in order to meet the criteria), rescreening for Hemoglobin, ALT, AST and coagulation function is allowed but only allowed once: absolute count of neutrophils (ANC) ≥1.5×109 /L, platelet ≥75×109 /L; Hemoglobin ≥90 g/L ; serum albumin ≥ 25g /L; Bilirubin ≤1.5 × ULN, ALT and AST ≤2.5 × ULN; In patients with liver metastasis, ALT and AST≤5 × ULN ; Creatinine clearance ≥50 mL/min (standard Cockcroft -Gault formula) or Cr ≤1.5 ×ULN: urinary protein ≥2+ or urinary protein quantitative <1.0 g/L International standardized ratio of coagulation function (INR) ≤ 1.5 × ULN, activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. If female, be either postmenopausal for at least 1 year with documented follicle stimulating hormone (FSH) >30 IU/L, or surgically sterile for at least 3 months, or if a woman of childbearing potential, must be non-pregnant confirmed by blood and urine pregnancy tests, and non-lactating. Female patients of childbearing potential must agree to use acceptable method(s) of contraception from consent through at least 6 months after drug infusion. Male patients of reproductive capacity must agree to use effective contraception from start of mobilization through at least 6 months after drug infusion Patients with chronic HBV infection with active disease who meet the criteria for anti HBV therapy (HBV DNA test is less than 2000 IU/ml) should be on a suppressive antiviral therapy prior to initiation of cancer therapy. Patients with a history of HCV infection should have completed curative antiviral treatment and HCV viral load below the limit of quantification. Patients with HCV Ab positive but HCV RNA negative due to prior treatment or natural resolution are eligible. Patients on concurrent HCV treatment should have HCV below the limit of quantification. Patients must be able to follow up after the treatment. Patients must understand and voluntarily sign the informed consent form. Exclusion Criteria: Patients will be excluded from participation for any of the following criteria: Received systemic or absorbable dosage of steroid hormone (prednisone or equivalent) of >10 mg/day in the 14 days prior to enrollment; Prednisone >10 mg/day Dexamethasone >1.5 mg/day. Currently using antibiotic. Tumors in hollow organs (Stomach, esophagus, intestine, urinary tract etc.). Present with symptomatic central nervous system metastasis or brain abscess at screening. Present with diverticulitis or conditions at screening that might promote the unintentional growth of anaerobic bacteria in nontarget lesions. Existing cardiac clinical symptoms or diseases that cannot be well controlled, such as: NYHA grade 2 or above heart failure; Unstable angina pectoris; Myocardial infarction occurred within 1 year; Patients with supraventricular or ventricular arrhythmias that have clinical significance and need treatment or intervention; Uncontrolled hypertension (systolic blood pressure) ≥160 mmHg and (diastolic blood pressure) ≥100 mmHg after drug treatment; Patients with valvular heart disease or mitral valve prolapse, aortic valve disease or other source of turbulent cardiac blood flow. Those who had received radiotherapy, chemotherapy, hormone therapy, surgery or molecular targeted therapy that ended fewer than 4 weeks before the first dose of study treatment (if nitrosourea or mitomycin chemotherapy,the interval between end of chemotherapy and first dose of study treatment must be no less than 6 weeks). Patients with active or uncontrolled infection or fever, >38.5℃, of unknown cause during screening or before the first administration of the study drug (according to the judgment of the researcher, fever caused by tumor can be included). Positive for the presence of human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2) (positive antigen/antibody and nucleic acid tests); or follow standard of care for HIV diagnosis. Patients with Anti-TP positive. Patients participating in other clinical studies or participating in other clinical studies within 4 weeks (or 5 half-lives of other study drugs) prior to enrollment and receiving experimental drug administration. Vaccination within 28 days of the first trial treatment, except for administration of inactivated vaccines and RNA vaccines (e.g., inactivated influenza vaccines and COVID-19 RNA vaccines) ; Received live or attenuated vaccines within 4 weeks of study drug administration, during treatment, or within 5 months of the last administration. In the judgment of the investigator, there are other factors that may lead to termination: for example, other serious diseases (including mental diseases) need to be treated together, there are serious abnormalities in laboratory examination, family or social factors, which may affect the safety of the patients or test data and sample collection. In the researcher's judgment, patients who are not suitable for other reasons. Documented salmonella infections within 6 months. Allergic to any study medications or rescue medications. Patients with implants such as pacemakers, prosthetic cardiac valves, or metal orthopedic prostheses.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Garin Liu
Phone
+886 905 891 942
Email
Garin.Liu@parexel.com
First Name & Middle Initial & Last Name or Official Title & Degree
Rosaria Vastella
Phone
+61 2 8870 3944
Email
Rosaria.Vastella@parexel.com
Facility Information:
Facility Name
Banner MD Anderson Cancer Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Madappa Kundranda
Phone
480-256-5484
Email
Madappa.Kundranda@bannerhealth.com
First Name & Middle Initial & Last Name & Degree
Anna Mahmoud
Phone
+1 414-241-6202
Email
anna.mahmoud@bannerhealth.com
First Name & Middle Initial & Last Name & Degree
Madappa Kundranda
Facility Name
Health Chao Family Comprehensive Cancer Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Warren Chow
Phone
714-456-5153
Email
wachow@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Jessica Spolarich
Phone
+1 714-509-2450
Email
jspolari@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Warren Chow
Facility Name
Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dipesh Uprety
Phone
313-576-8746
Email
upretyd@karmanos.org
First Name & Middle Initial & Last Name & Degree
Kelsey Desrosier
Phone
+1 313-576-9697
Email
Desrosierk@karmanos.org
First Name & Middle Initial & Last Name & Degree
Dipesh Uprety, MD
First Name & Middle Initial & Last Name & Degree
Elisabeth Heath
Facility Name
University of Cincinnati Cancer Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45267
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Trisha Wise-Draper
Phone
513-558-2826
Email
wiseth@ucmail.uc.edu
First Name & Middle Initial & Last Name & Degree
Bethany Fuhrman
Phone
+1 513-584-8162
Email
fuhrmaba@ucmail.uc.edu
First Name & Middle Initial & Last Name & Degree
Trisha Wise-Draper
Facility Name
China Medical University Hospital
City
Taichung City
ZIP/Postal Code
40447
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ching-Yun Hsieh
Phone
+886-4-22052121 ext.5057
Email
D7995@mail.cmuh.org.tw
First Name & Middle Initial & Last Name & Degree
Yu-Ting Ho
Phone
+886-4-22052121 ext.5057
Email
blessyou1982@gmail.com
Facility Name
Taipei Medical University Hospital
City
Taipei City
ZIP/Postal Code
110301
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi-Wen Huang
Phone
+886-970-405-048
Email
yiwenhuang@tmu.edu.tw
First Name & Middle Initial & Last Name & Degree
Ichen Tsai
Phone
+886-909-705-050
Email
ichen.tsai@doint.com.tw
Facility Name
Taipei Veterans General Hospital
City
Taipei City
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mu-Hsin Chang
Phone
+886-2-28712121 ext 2573
Email
ptchang@vghtpe.gov.tw
First Name & Middle Initial & Last Name & Degree
Ling-Ling Chiu
Phone
+886-2-28712121 ext 2999
Email
chiu458151@gmail.com
Facility Name
Linkou Chang Gung Memorial Hospital
City
Taoyuan City
ZIP/Postal Code
333
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yung-Chang Lin
Phone
+886-975-368-115
Email
yclinof@adm.cgmh.org.tw
First Name & Middle Initial & Last Name & Degree
Hsiao Ying Kuo
Phone
+886-975-056-094
Email
hlsweetygirl@cgmh.org.tw

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of SGN1 in Patients With Advanced Solid Tumor

We'll reach out to this number within 24 hrs